BLOG

The Search Intensifies for Cancer Treatments with Fewer Side Effects

Dorigo is principal investigator of a clinical trial of a new immunotherapy called maveropepimut-S. It’s being developed by IMV Inc., a pharmaceutical company focused on innovative immune cell activating approaches.